RESULTS	Median time to first skeletal-related event in the enzalutamide ( n = 800 ) and placebo ( n = 399 ) groups was 167 months ( 95 % CI 146 to 191 ) and 133 months ( 95 % CI 99 to not yet reached ) , respectively ( hazard ratio [ HR ] 069 [ 95 % CI 057-084 ] ; p = 00001 ) .\